Vireo Growth (VREOF) Cash & Current Investments (2020 - 2026)
Vireo Growth (VREOF) reported Cash & Current Investments of $153.2 million for Q1 2026, up 74.19% on a YoY basis from $88.0 million in Q1 2025, and up 7.28% sequentially from $142.8 million in Q4 2025.
Vireo Growth (VREOF) Cash & Current Investments (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Cash & Current Investments data on file, last reported at $153.2 million in Q1 2026.
- For the quarter ending Q1 2026, Cash & Current Investments rose 74.19% year-over-year to $153.2 million; the trailing twelve-month figure through Mar 2026 stood at $153.2 million (up 74.19% YoY), and the FY2025 full-year result was $142.8 million, up 52.12% from the prior year.
- Cash & Current Investments advanced to $153.2 million in Q1 2026, from $142.8 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $153.2 million in Q1 2026 to a low of $7.3 million in Q3 2024.
- A 5-year average of $49.6 million and a median of $17.0 million in 2022 frame the typical range for Cash & Current Investments.
- Across the five-year window, Cash & Current Investments tumbled 78.79% in 2022 and jumped 1528.49% in 2025, its largest moves.
- Tracing VREOF's Cash & Current Investments over 5 years: stood at $15.1 million in 2022, then increased by 18.17% to $17.9 million in 2023, then soared by 424.36% to $93.9 million in 2024, then jumped by 52.12% to $142.8 million in 2025, then grew by 7.28% to $153.2 million in 2026.
- Business Quant data shows VREOF's Cash & Current Investments at $153.2 million in Q1 2026, $142.8 million in Q4 2025, and $118.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.60 Bn | 87.73 Bn | - | 1.86 Bn |
| 2 | Teva Pharmaceutical Industries | 35.90 Bn | 32.16 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 32.49 Bn | 30.55 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | 4.06 Bn |
| 5 | United Therapeutics | 23.13 Bn | 20.97 Bn | 648.10 Mn | 2.15 Bn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.75 Bn | 16.43 Bn | 800.70 Mn | 1.32 Bn |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Vireo Growth | 10.52 Bn | 10.37 Bn | 59.30 Mn | 153.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 153.20 Mn |
| Dec 31, 2025 | 142.80 Mn |
| Sep 30, 2025 | 118.55 Mn |
| Jun 30, 2025 | 100.41 Mn |
| Mar 31, 2025 | 87.95 Mn |
| Dec 31, 2024 | 93.87 Mn |
| Sep 30, 2024 | 7.28 Mn |
| Jun 30, 2024 | 11.23 Mn |
| Mar 31, 2024 | 12.60 Mn |
| Dec 31, 2023 | 17.90 Mn |
| Sep 30, 2023 | 13.30 Mn |
| Jun 30, 2023 | 11.35 Mn |
| Mar 31, 2023 | 10.35 Mn |
| Dec 31, 2022 | 15.15 Mn |
| Sep 30, 2022 | 21.84 Mn |
| Jun 30, 2022 | 16.97 Mn |
| Mar 31, 2022 | 8.60 Mn |
| Dec 31, 2021 | 15.16 Mn |
| Sep 30, 2021 | 11.78 Mn |
| Jun 30, 2021 | 20.83 Mn |